This study involves atopic dermatitis, a long-term skin condition that causes red, itchy, and inflamed skin. The treatment being tested is called BFB759, which is given as an injection under the skin. Some people in the study will receive BFB759 while others will receive placebo. The purpose of this study is to evaluate how well BFB759 works in adults with atopic dermatitis and to check if it is safe to use.
The study is designed for adults between 18 and 75 years old who have had atopic dermatitis for at least one year and whose condition is moderate to severe and not well controlled by creams or ointments applied to the skin. Participants will be randomly assigned to receive either BFB759 or placebo for a treatment period of 14 weeks. During the study, participants will need to attend regular visits and avoid using certain other medications.
The main goal is to measure changes in the severity and extent of skin symptoms using a scoring system that looks at redness, thickness, scratching marks, and the area of skin affected. The study will also track how many people experience significant improvement in their symptoms, changes in the amount of body surface area affected by the condition, overall disease severity scores, and improvements in itching. The safety of the treatment will be monitored by recording any unwanted side effects that occur during the study.
Bulgaria 
Czechia 
Germany 
Poland 
Spain 
